Related Experiment Video
Updated: Aug 13, 2026
07:59
Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
Published on: April 4, 2022
Evolving treatment strategies for chronic refractory angina
Eric H Yang1, Gregory W Barsness
1Division of Cardiovascular Diseases and Internal Medicine, Mayo College of Medicine, Rochester, MN 55905, USA.
Expert Opinion on Pharmacotherapy
|February 2, 2006
Summary
Chronic refractory angina affects 5-15% of US patients despite optimal treatment. This review explores new drug therapies like L-arginine and ranolazine, plus devices such as enhanced external counterpulsation for managing this condition.
Area of Science:
- Cardiology
- Pharmacology
- Interventional Cardiology
Background:
- Chronic refractory angina impacts 5-15% of the 12 million U.S. patients with chronic angina, persisting despite optimal medical therapy.
- Patients experience persistent angina symptoms alongside objective evidence of myocardial ischemia.
Purpose of the Study:
- To review evolving pharmacological therapies for chronic refractory angina.
- To briefly discuss emerging devices and invasive procedures for managing this condition.
Main Methods:
- Literature review focusing on pharmacological agents.
- Summary of evidence for devices and invasive procedures.
Main Results:
- Key pharmacological therapies reviewed include L-arginine, ivabradine, ranolazine, nicorandil, and trimetazidine.
- Devices and procedures discussed encompass enhanced external counterpulsation, spinal cord stimulation, and transmyocardial revascularization.
Conclusions:
- Several evolving pharmacological and interventional options show promise for managing chronic refractory angina.
- Further research is needed to establish the full efficacy and safety profiles of these novel treatments.
Related Concept Videos
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
01:20Angina V: Nursing Management
Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:27Angina II: Classification
Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...